Avalanche CEO: Disappointed in market's reaction of study

Shares of Avalanche Biotechnologies plummeted 56 percent on study results from its lead candidate to treat a chronic eye disease. Founder and CEO, Thomas Chalberg, is disappointed in the market's reaction.